Pan Pan1, Lijuan Wang2, Yanjun Wang3, Li Shen1, Pingping Zheng1, Chunli Bi1, Anning Zhang1, Yaogai Lv1, Zhiqiang Xue1, Mengzi Sun1, Chong Sun1, Jiagen Li1, Lina Jin1, Yan Yao4. 1. Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education and Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China. 2. Department of Neurology, The Neuroscience Center, The First Hospital of Jilin University, Jilin University, Changchun, China. 3. Nursing Department, the Second Hospital of Jilin University, Changchun, China. 4. Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education and Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China, yaoyan@jlu.edu.cn.
Abstract
BACKGROUNDS: We performed this systematic review and meta-analysis to compare the efficacy of new-generation tyrosine kinase inhibitors (NG-TKIs; including dasatinib, nilotinib, bosutinib, radotinib, and ponatinib) versus imatinib for patients with newly diagnosed chronic myeloid leukemia (CML). SUMMARY: We identified randomized controlled trials comparing the efficacy of NG-TKIs versus imatinib as the first-line treatment for CML patients by searching the PubMed, Cochrane library, and EMBASE databases. Two reviewers independently extracted data and assessed study quality. A meta-analysis was performed to calculate risk ratios and 95% CIs using a fixed-effects model.Our study included 10 trials. Overall, treatment with NG-TKIs significantly improved the major molecular response and MR4.5 at all time points, and early molecular response at 3 months. Importantly, overall survival (OS) was significantly higher with the NG-TKIs at 12 months. Besides, NG-TKI-treated patients showed a significantly lower CML-related death and progression to the accelerated phase/blast crisis. Key Messages: In first-line treatment, NG-TKIs are superior to imatinib regarding OS at 12 months, and because molecular response rates were higher with the NG-TKIs at all time points, the NG-TKIs favor treatment-free remission.
BACKGROUNDS: We performed this systematic review and meta-analysis to compare the efficacy of new-generation tyrosine kinase inhibitors (NG-TKIs; including dasatinib, nilotinib, bosutinib, radotinib, and ponatinib) versus imatinib for patients with newly diagnosed chronic myeloid leukemia (CML). SUMMARY: We identified randomized controlled trials comparing the efficacy of NG-TKIs versus imatinib as the first-line treatment for CMLpatients by searching the PubMed, Cochrane library, and EMBASE databases. Two reviewers independently extracted data and assessed study quality. A meta-analysis was performed to calculate risk ratios and 95% CIs using a fixed-effects model.Our study included 10 trials. Overall, treatment with NG-TKIs significantly improved the major molecular response and MR4.5 at all time points, and early molecular response at 3 months. Importantly, overall survival (OS) was significantly higher with the NG-TKIs at 12 months. Besides, NG-TKI-treated patients showed a significantly lower CML-related death and progression to the accelerated phase/blast crisis. Key Messages: In first-line treatment, NG-TKIs are superior to imatinib regarding OS at 12 months, and because molecular response rates were higher with the NG-TKIs at all time points, the NG-TKIs favor treatment-free remission.
Authors: Jim Canet; Pascale Cony-Makhoul; Sébastien Orazio; Edouard Cornet; Xavier Troussard; Marc Maynadié; Gabriel Étienne; Alain Monnereau Journal: Cancer Med Date: 2021-09-22 Impact factor: 4.452
Authors: José Luis Marín-Rubio; Rachel E Peltier-Heap; Maria Emilia Dueñas; Tiaan Heunis; Abeer Dannoura; Joseph Inns; Jonathan Scott; A John Simpson; Helen J Blair; Olaf Heidenreich; James M Allan; Jessica E Watt; Mathew P Martin; Barbara Saxty; Matthias Trost Journal: J Med Chem Date: 2022-09-12 Impact factor: 8.039